Morgan Stanley is tactically bullish on Giant Biogene (02367.HK)

Overview

This is a Morgan Stanley Asia-Pacific research report presenting a tactical view on Giant Biogene Holding Co Ltd (02367.HK). The core conclusion is that the report sees a high probability of the company's stock price rising over the next 30 days because the market has not yet fully reflected the strong 2Q26 sales update, the launch of its first recombinant collagen injectable, and signals that 1H26 sales performance is better than the model.

Core views

The report's core views include: first, Giant Biogene's stock price reacted insufficiently after the 2Q26 sales update and new product launch, creating a short-term risk-reward opportunity; second, against the backdrop of potentially improved market risk appetite driven by easing tensions in the Middle East, the stock may be more easily screened by investors as an attractive target; third, the company's 1H26 sales may achieve about 20% h/h growth, indicating sales momentum stronger than the original model; fourth, 12x N12M P/E and a 4%-5% dividend yield are considered materially undervalued relative to its growth characteristics.

Analysis framework

The report uses a combination of tactical event-driven analysis and valuation comparison: it first judges the short-term stock price direction over the next 30 days, then evaluates risk-reward by combining sales tracking, new product launches, market risk appetite, N12M P/E, dividend yield, target P/E, and PEG.

Methodology notes

• Scenario analysisTactical scenario probability

  Probability of rising over the next 30 days

  The report estimates the probability of this upside scenario at about 70%-80% and states that the probability is based on the analyst's subjective assessment of scenario likelihood.

• Valuation methodsTarget P/E valuation method

  2026e target P/E of 21x

  The report states that base-case valuation uses a 2026e target P/E of 21x and believes the company's biotech advantages may be undervalued by the market before sales growth accelerates.

• Valuation methodsPEG

  1.4x PEG

  The 21x 2026e target P/E implies a 1.4x PEG based on 2026-28e EPS CAGR, used to measure the match between valuation and earnings growth.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Giant Biogene Holding Co Ltd (02367.HK)

  The report's core covered name, with a tactical view of stock price appreciation over the next 30 days.

  Strengths

  Strong 2Q26 sales update; first recombinant collagen injectable has been launched; 1H26 sales tracking is ahead of the model; valuation is 12x N12M P/E with a 4%-5% dividend yield; the report believes its biotech advantages may be undervalued in the short term.

  Weaknesses

  The stock price previously did not react positively to the sales update and new product launch, indicating that further catalysts are still needed for market recognition; the report also notes a risk of OPM compression.

  Comparison

  The report does not provide a quantified peer comparison, but believes the current valuation is clearly low relative to its growth profile, and uses 21x 2026e target P/E and 1.4x PEG as base-case valuation references.

  Risks

  Delays in approval of new medical aesthetics products, weakening momentum of recombinant collagen products, intensifying industry competition, macro weakness, and faster-than-expected OPM compression.

Key data

• Report date2026-06-15 01:34 AM GMTThe publication time disclosed on the report's cover page.
• Tactical horizonNext 30 daysThe report explicitly states that it expects the stock price to rise on an absolute return basis over the next 30 days.
• Scenario probability70%-80%The report describes this probability as "very likely" and notes that it is a subjective scenario probability.
• 1H26 sales growth viewAbout 20% h/hThe report states that 1H26 sales tracking is ahead of the model, and sales may currently grow about 20% quarter over quarter.
• Current valuation12x N12M P/EThe report believes this valuation is clearly undervalued for a growth company.
• Dividend yield4%-5%Part of the basis for the undervaluation view.
• Base-case valuation parameter2026e target P/E 21xUsed by the report for base-case valuation assessment.
• Implied PEG1.4xBased on 2026-28e EPS CAGR.
• Target price history2026-04-21: 43The most recent target price history value shown in the chart title; the report body does not provide the current price.

Impact & implications

If the report's view proves correct, Giant Biogene may achieve valuation re-rating amid improved short-term risk appetite, continued validation from sales data, and expectations for ramp-up in new product volume. Over the longer term, whether the market re-rates the company's biotech advantages will depend on whether sales growth can accelerate, whether core brand recognition can improve, and whether the recombinant collagen and medical aesthetics product lines can continue to deliver.

Risks

• OPM contracts faster than expected.
• Delays in approval of new medical aesthetics products.
• Weakening momentum in recombinant collagen products.
• Macro weakness combined with intensifying industry competition.
• The report discloses that Morgan Stanley may have business relationships or potential conflicts of interest with companies under its coverage, and investors should not rely on a single research report alone for decision-making.

What to watch

• Whether 1H26 sales deliver about 20% h/h growth.
• Sales ramp-up and channel feedback after the launch of the first recombinant collagen injectable.
• Core brand awareness and consumer acceptance of recombinant collagen skincare products.
• Approval progress for new medical aesthetics products and the pace of subsequent product launches.
• Changes in OPM, the intensity of industry competition, and the health of China's beauty consumption.
• Whether market risk appetite improves due to macro events such as easing tensions in the Middle East.